$RCUS
Arcus Biosciences, Inc. Stock $rcus

$rcus Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000172452124000160 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$48.00M	$32.00M
YoY Change		50.0%	-4.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$30.00M	$30.00M
YoY Change		0.0%	14.09%
% of Gross Profit
Research & Development		$123.0M	$82.00M
YoY Change		50.0%	6.93%
% of Gross Profit
Depreciation & Amortization		$2.000M	$1.000M
YoY Change		100.0%	-35.9%
% of Gross Profit
Operating Expenses		$153.0M	$112.0M
YoY Change		36.61%	8.76%
Operating Profit		-$105.0M	-$80.00M
YoY Change		31.25%	15.28%
Interest Expense		$14.00M	$12.00M
YoY Change		16.67%	139.38%
% of Operating Profit
Other Income/Expense, Net		$13.00M	$11.00M
YoY Change		18.18%	145.65%
Pretax Income		-$92.00M	-$69.00M
YoY Change		33.33%	6.29%
Income Tax		$0.00	$2.000M
% Of Pretax Income
Net Earnings		-$92.00M	-$71.00M
YoY Change		29.58%	9.37%
Net Earnings / Revenue		-191.67%	-221.88%
Basic Earnings Per Share		-$1.00	-$0.94
Diluted Earnings Per Share		-$1.00	-$0.95
COMMON SHARES
Basic Shares Outstanding	91.51M shares	91.43M shares	74.50M
Diluted Shares Outstanding		91.40M shares	74.60M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.089B	$799.0M
YoY Change	36.3%	-23.82%
Cash & Equivalents	$201.0M	$184.0M
Short-Term Investments	$888.0M	$615.0M
Other Short-Term Assets	$17.00M	$27.00M
YoY Change	-37.04%	24.86%
Inventory
Prepaid Expenses
Receivables	$21.00M	$56.00M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.127B	$882.0M
YoY Change	27.78%	-19.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.00M	$50.00M
YoY Change	-4.0%	47.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M	$151.0M
YoY Change	-98.68%	5.49%
Other Assets	$75.00M	$108.0M
YoY Change	-30.56%	919.06%
Total Long-Term Assets	$125.0M	$309.0M
YoY Change	-59.55%	5.57%
TOTAL ASSETS
Total Short-Term Assets	$1.127B	$882.0M
Total Long-Term Assets	$125.0M	$309.0M
Total Assets	$1.252B	$1.191B
YoY Change	5.12%	-14.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.00M	$17.00M
YoY Change	-23.53%	61.2%
Accrued Expenses	$97.00M	$72.00M
YoY Change	34.72%	250.74%
Deferred Revenue	$105.0M	$103.0M
YoY Change	1.94%	-0.28%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$215.0M	$200.0M
YoY Change	7.5%	12.88%
LONG-TERM LIABILITIES
Long-Term Debt	$47.00M	$0.00
YoY Change
Other Long-Term Liabilities	$136.0M	$145.0M
YoY Change	-6.21%	796.94%
Total Long-Term Liabilities	$136.0M	$145.0M
YoY Change	-6.21%	796.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$215.0M	$200.0M
Total Long-Term Liabilities	$136.0M	$145.0M
Total Liabilities	$351.0M	$345.0M
YoY Change	1.74%	-50.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.038B	-$768.0M
YoY Change	35.16%	61.72%
Common Stock	$1.602B	$1.291B
YoY Change	24.09%	18442757.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$565.0M	$520.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.252B	$1.191B
YoY Change	5.12%	-14.55%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$92.00M	-$71.00M
YoY Change	29.58%	9.37%
Depreciation, Depletion And Amortization	$2.000M	$1.000M
YoY Change	100.0%	-35.9%
Cash From Operating Activities	$26.00M	-$63.00M
YoY Change	-141.27%	-22.18%
INVESTING ACTIVITIES
Capital Expenditures	$1.000M	$10.00M
YoY Change	-90.0%	-858.73%
Acquisitions
YoY Change
Other Investing Activities	-$28.00M	$21.00M
YoY Change	-233.33%	-15.2%
Cash From Investing Activities	-$29.00M	$11.00M
YoY Change	-363.64%	-53.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	48.00M	6.000M
YoY Change	700.0%	137.06%
NET CHANGE
Cash From Operating Activities	26.00M	-63.00M
Cash From Investing Activities	-29.00M	11.00M
Cash From Financing Activities	48.00M	6.000M
Net Change In Cash	45.00M	-46.00M
YoY Change	-197.83%	-16.34%
FREE CASH FLOW
Cash From Operating Activities	$26.00M	-$63.00M
Capital Expenditures	$1.000M	$10.00M
Free Cash Flow	$25.00M	-$73.00M
YoY Change	-134.25%	-8.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001724521
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48000000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	232000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86000000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	123000000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	82000000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	347000000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247000000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30000000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30000000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92000000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	88000000	usd
	dei	Document Type DocumentType	10-Q
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91400000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91400000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74600000	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-93000000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	635000000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1000000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-71000000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	520000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	462000000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2000000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-15000000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3000000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-51000000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-218000000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	673000000	usd
	rcus	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	837000000	usd
	rcus	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	20000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	187000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	142000000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000.0	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75500000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1311000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-849000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	462000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1095000000	usd
CY2024Q1	rcus	Allocation Of Transaction Price AllocationOfTransactionPrice	522000000	usd
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3898435
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3928 Point Eden Way
	dei	Entity Address City Or Town EntityAddressCityOrTown	Hayward
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94545
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Arcus Biosciences, Inc.
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Local Phone Number LocalPhoneNumber	694-6200
	dei	Trading Symbol TradingSymbol	RCUS
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	91511609	shares
	dei	Entity File Number EntityFileNumber	001-38419
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	City Area Code CityAreaCode	510
CY2024Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	20000000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	112000000	usd
	us-gaap	Operating Expenses OperatingExpenses	459000000	usd
	us-gaap	Operating Expenses OperatingExpenses	335000000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-80000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-227000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-249000000	usd
CY2023Q3	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	12000000	usd
	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	40000000	usd
	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	30000000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	38000000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28000000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-189000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-221000000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-71000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-189000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-226000000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.07
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73600000	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-71000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-189000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-226000000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4000000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-188000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-222000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	632000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	38000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	831000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	107000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	106000000	usd
CY2023Q4	us-gaap	Assets Assets	1095000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	91000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	76000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	184000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	307000000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	136000000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91500000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1602000000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1038000000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	565000000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1252000000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q3	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001 Per Share
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	153000000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-105000000	usd
CY2024Q3	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	14000000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1000000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1000000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2000000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2000000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13000000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92000000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-92000000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.07
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89600000	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-92000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201000000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	888000000	usd
CY2024Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	16000000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22000000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1127000000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	2000000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48000000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	75000000	usd
CY2024Q3	us-gaap	Assets Assets	1252000000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	13000000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	105000000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	97000000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	215000000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	289000000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	47000000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000.0	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91500000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75500000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	657000000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	600000000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20000000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18000000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-75000000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	566000000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	228000000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	707000000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20000000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2000000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-92000000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	565000000	usd
	us-gaap	Profit Loss ProfitLoss	-189000000	usd
	us-gaap	Profit Loss ProfitLoss	-226000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	59000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	55000000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7000000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5000000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5000000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6000000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	20000000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	19000000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	13000000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2000000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-32000000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-16000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2000000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-14000000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	13000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70000000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	871000000	usd
	rcus	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	726000000	usd
	rcus	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	15000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-135000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	166000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	228000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	47000000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6000000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5000000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2000000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	279000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	130000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	209000000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	204000000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6000000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization, liquidity and capital resources<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in multiple Phase 3 registrational studies targeting lung and gastrointestinal ("GI") cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, we had cash, cash equivalents and marketable securities of $1.1 billion, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.</span></div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q3	us-gaap	Investments And Cash InvestmentsAndCash	1100000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48000000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	232000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86000000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	33000000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	28000000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	212000000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	79000000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	394000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	398000000	usd
CY2024Q1	rcus	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress And Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice	107000000	usd
	rcus	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Earnings Per Share Basic ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueEarningsPerShareBasic	1.19
	rcus	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Earnings Per Share Diluted ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueEarningsPerShareDiluted	1.19
CY2024Q1	rcus	Option Payment For Domvanalimab OptionPaymentForDomvanalimab	87000000	usd
CY2024Q1	rcus	Option Payment Received For Etrumadenant OptionPaymentReceivedForEtrumadenant	100000000	usd
CY2024Q1	rcus	Deferred Revenues At Amendment Closing Date DeferredRevenuesAtAmendmentClosingDate	335000000	usd
CY2024Q1	rcus	Option Payment Received For Etrumadenant OptionPaymentReceivedForEtrumadenant	100000000	usd
CY2024Q1	rcus	Option Payment For Domvanalimab OptionPaymentForDomvanalimab	87000000	usd
CY2024Q1	rcus	Deferred Revenues At Amendment Closing Date DeferredRevenuesAtAmendmentClosingDate	335000000	usd
CY2024Q1	rcus	Allocation Of Transaction Price AllocationOfTransactionPrice	522000000	usd
CY2024Q1	rcus	Etrumadenant License And Research And Development Activities EtrumadenantLicenseAndResearchAndDevelopmentActivities	210000000	usd
CY2024Q1	rcus	Quemliclustat License And Research And Development Activities QuemliclustatLicenseAndResearchAndDevelopmentActivities	168000000	usd
CY2024Q1	rcus	Zimberelimab Research And Development And Commercial Activities ZimberelimabResearchAndDevelopmentAndCommercialActivities	33000000	usd
CY2024Q1	rcus	Access Rights AccessRights	57000000	usd
CY2024Q1	rcus	Option Continuation Periods OptionContinuationPeriods	20000000	usd
CY2024Q1	rcus	Rights To Certain Studies RightsToCertainStudies	34000000	usd
CY2024Q1	rcus	Allocation To Performance Obligations AllocationToPerformanceObligations	522000000	usd
	rcus	Allocation To Performance Obligations AllocationToPerformanceObligations	35000000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	3000000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3000000	usd
CY2024Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3000000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000000	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.024
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.022
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15800000	shares
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19000000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	59000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55000000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1090000000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1091000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	866000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	866000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	201000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	127000000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	888000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	632000000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	2000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	107000000	usd
CY2024Q3	rcus	Cash Cash Equivalents And Available For Sale Investments CashCashEquivalentsAndAvailableForSaleInvestments	1091000000	usd
CY2023Q4	rcus	Cash Cash Equivalents And Available For Sale Investments CashCashEquivalentsAndAvailableForSaleInvestments	866000000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	21	position
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	105	position
CY2024Q3	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2023Q3	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2023	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201000000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	184000000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3000000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3000000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	204000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	187000000	usd
CY2024Q3	rcus	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	17000000	usd
CY2023Q4	rcus	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	30000000	usd
CY2024Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	5000000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	4000000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34000000	usd
CY2024Q3	rcus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	57000000	usd
CY2023Q4	rcus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	36000000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27000000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	26000000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11000000	usd
CY2024Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	2000000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3000000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	97000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	76000000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	50000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	47000000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	1000000	usd
CY2024Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1339
	rcus	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	12000000	usd
	rcus	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	12000000	usd
	rcus	Cash Received From Tenant Improvement Allowances CashReceivedFromTenantImprovementAllowances	0	usd
	rcus	Cash Received From Tenant Improvement Allowances CashReceivedFromTenantImprovementAllowances	8000000	usd
	rcus	Recognition Of Tenant Improvement Allowance Receivable RecognitionOfTenantImprovementAllowanceReceivable	0	usd
	rcus	Recognition Of Tenant Improvement Allowance Receivable RecognitionOfTenantImprovementAllowanceReceivable	4000000	usd
CY2024Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	20000000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	20000000	usd
CY2024Q3	us-gaap	Security Deposit SecurityDeposit	3000000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	3000000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001724521-24-000160-index-headers.html	Edgar Link	pending
0001724521-24-000160-index.html	Edgar Link	pending
0001724521-24-000160.txt	Edgar Link	pending
0001724521-24-000160-xbrl.zip	Edgar Link	pending
a2024q3exhibit311.htm	Edgar Link	pending
a2024q3exhibit312.htm	Edgar Link	pending
a2024q3exhibit321.htm	Edgar Link	pending
a2024q3exhibit322.htm	Edgar Link	pending
ex101.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rcus-20240930.htm	Edgar Link	pending
rcus-20240930.xsd	Edgar Link	pending
rcus-20240930_g1.jpg	Edgar Link	pending
rcus-20240930_g2.jpg	Edgar Link	pending
rcus-20240930_g3.jpg	Edgar Link	pending
rcus-20240930_g4.jpg	Edgar Link	pending
rcus-20240930_g5.jpg	Edgar Link	pending
rcus-20240930_g6.jpg	Edgar Link	pending
rcus-20240930_g7.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
rcus-20240930_def.xml	Edgar Link	unprocessable
rcus-20240930_lab.xml	Edgar Link	unprocessable
rcus-20240930_pre.xml	Edgar Link	unprocessable
rcus-20240930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
rcus-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RCUS
Arcus Biosciences, Inc. Stock $rcus

2024 Q4 Form 10-Q Financial Statement

#000172452124000160 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCUS Arcus Biosciences, Inc. Stock $rcus

2024 Q4 Form 10-Q Financial Statement

#000172452124000160 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCUS
Arcus Biosciences, Inc. Stock $rcus